Investments in pharma R&D has substantially increased over the last decades. Yet there appears to be no clear correlation to the number of newly approved drugs. This fact is accompanied by ever-increasing healthcare costs, fueled by an aging population and the parallel rise in the chronic disease burden. Late stage drug development is the most costly area of drug R&D and it also has the highest attrition rate with huge financial implications for sponsors. Increasing the probability of success and the number of new chemical entities in pharmaceutical pipelines requires optimization of drug discovery and clinical translational efforts, along with a decrease of late-stage drug failures.

“We are cognizant that the realization of the promise of genomics and ‘big data’ will require generating data and knowledge at an unprecedented scale and no single organization has either the scientific or financial resource to tackle this alone. We have become more mature as a community in finding ways to work together in an ‘open innovation’ space where all parties are comfortable that there will either be no IP emerging from the research or that IP can be managed within the PPP.”

Sally John, PhD, Vice President of Translational Biology, Biogen Inc.

To reverse and overcome these ongoing negative trends, pharmaceutical companies are employing novel strategies that represent a paradigm shift from existing approaches. They are building on innovation, collaboration, and the strengths and input of stakeholders in the health system who share their goal of delivering effective and sustainable healthcare solutions for the population.

One of these new approaches is establishing precompetitive public–private partnerships (PPPs) to solve challenges that are too large for single organizations to effectively address on their own. These partnerships enable researchers to gain valuable insights through pooled knowledge and resources to support advances in the development of new medicines for a wide range of serious and life-threatening diseases.

Public-private partnerships (PPPs):

  • Support open innovation and pre-competitive research
  • Rely on open innovation networks
  • Link the know-how and resources of the pharmaceutical industry with external pools of knowledge, especially in universities and biotechnology companies
  • Have been pioneered in the area of neglected diseases
  • Have been encouraged and fostered by the US Food and Drug Administration and the NIH

Benefits of PPPs:

  • Shared risk and costs that aim to tackle emerging areas of complex biology
  • Bring together expertise and ideas from public and private sectors that lead to greater diversity of thought.
  • Can help sculpt a research landscape conducive to acceleration of the drug discovery process
  • Early delivery of promising new treatments to patients suffering from debilitating diseases.
  • Researchers on both sides gain a new network, learn new practices and share a sense of community and goals

PPP Challenges

  • Establishing the scientific goals, contract terms, and conditions on which all parties agree
  • Maintaining open and transparent communication within a large PPP, critical to building and maintaining trust
  • Different perspectives can sometimes serve as obstacles to effective collaborations, yet when managed and challenged correctly they can also promote innovative thinking

Examples of successful PPP examples:

  • Open Targets: Innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritization
  • FinnGen: Research project that combines genome information with digital health care/electronic health data from Finnish registries
  • Structural Genomics Consortium: Supports the discovery of new medicines through open access research
  • Regeneron Genetics Center – UK Biobank: Generates genetic sequencing data from 500,000 volunteer participants and pairs this genetic data with anonymized clinical data to conduct analyses to learn more about human genetics and biology. UK Biobank is funded by numerous biopharma industry partners who see the value of genetic research in drug discovery and development.

“Genetic research is a game of numbers – you need an enormous sample size to begin to connect the dots between genetic variations and potential links to diseases. In order to obtain this amount of “big data,” it makes sense for public and private organizations to work together to ethically share data for the greater good. By combining public and private resources (both in terms of data and funding), we have more scientific minds analyzing greater amounts of data, in turn accelerating the drug development process and hopefully bringing new therapeutics to people in need faster.”

Aris Baras, MD, Vice President, Head, Regeneron Genetics Center

We have an impressive panel scheduled at PMWC 2018 Duke – September 24-25, Washington Duke Inn, Duke University Campus, focused on “Public-Private Partnerships” and chaired by Dr. Robert Califf (Duke University School of Medicine, former FDA Commissioner). Panel participants include Aris Baras, MD (Regeneron), Sally Jones, PhD (Biogen), Dr. Stacey Gabriel (Broad Institute), Dr. Howard Jacob (Abbvie) which promises to be an engaging discussion.

It is not too late to register for conference attendance and be part of these critical discussions that have the potential to shape solutions to some of our most pressing healthcare challenges.

Best regards,
Tal Behar
Co-founder & President
PMWC

Interview with Daniel Chen from IGM Biosciences

Q: Checkpoint inhibitors, particularly with PD-L1/PD-1 targeting agents, have benefited a broad range of patients with cancer. How will we improve on this?

A: It’s true that PD-L1/PD-1 inhibitors have led to durable responses in a subset of patients, and survival benefit in many of the patients treated- either as monotherapy or combination.

Read More

Call from PMWC 2019 Silicon Valley Program Committee – We Must Accelerate and Deliver on the Promise of Precision Medicine

Precision medicine advancements are real as demonstrated by the high volume of molecular, “precise” drugs on the market, which are based on extensive molecular and translational understanding of the specific drug targets.

Read More

#AI Play in Patient Diagnosis? How Can We Prepare the Next Generation to Make Sense of Enormous Amounts of Health-related Data?

What role should artificial intelligence play in patient diagnosis? How can we best prepare the next generation to make sense of enormous amounts of health-related data? These were just a few of the questions explored at the 15th Precision Medicine World Conference held at Duke University September 24-25, 2018.

Read More

Interview with Daniella Beller, Manager, Maccabi Research Institute Biobank

Q: What makes the Maccabi Research Institute biobank unique?

A: To explain the uniqueness of the Maccabi Biobank (named “Tipa” in Hebrew which means “drop” or “just a little”), first you must know a little about Maccabi.

Read More

Why We Need Public-Private Partnerships (PPP) To Foster Drug Discovery

Investments in pharma R&D has substantially increased over the last decades. Yet there appears to be no clear correlation to the number of newly approved drugs. This fact is accompanied by ever-increasing healthcare costs, fueled by an aging population and the parallel rise in the chronic disease burden.

Read More

Precision Medicine: A Decade of Improving the Standard of Care

In January, PMWC will host its 2019 Silicon Valley event, the largest Precision Medicine conference in the world with over 2,500 attendees gathering at the Santa Clara Convention Center. We are humbled and honored to have reached this stage of growth and are looking forward to continuing our work with key stakeholders and decision makers across the industry to ever strengthen this forum for exchange of critical and timely topics, to move the field of precision medicine forward and to improve the Standard of Care.

Read More

Interview with David Hong from Karius

Q: What need is Karius addressing?

A: Physicians often have difficulty pinpointing the exact pathogen that is causing disease. Conventional diagnostics like blood cultures or PCR can have poor sensitivity due to pretreatment with antibiotics, the breadth of potential pathogens present, and the requirement for invasive procedures to access deep-seated infections.

Read More

Interview with Charles Jaffe, MD, PhD from HL7

Q: What need is HL7 addressing?

A: For more than three decades, HL7 has provided the platform to enable global health data interoperability. This is more important than ever, as the cost of healthcare has increased exponentially, and the complexity of clinical evidence has grown to an almost unmanageable state.

Read More

Interview with Eden Haverfield from Invitae

Q: What need is Invitae addressing?

A: Our mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae is uniquely positioned to answer some of life’s most serious and complex questions with the highest quality genetics and at an affordable price.

Read More

Call by Ralph Snyderman (Duke U.) for Big Changes to Get to the Next Level of Precision Medicine

Beyond next-generation gene sequencing and developing diagnostic tools and targeted therapies, theoverall approach to clinical care has to be re-envisioned to fulfill the promise of precision medicine. Care must move from sporadic treatment of episodic disease (a reactive mode) to predicting disease and then acting to prevent and mitigate it (a proactive mode).

Read More

Interview with William Hearl From Immunomic Therapeutics, Inc.

Q: What need is Immunomic Therapeutics, Inc. addressing?

A: Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory.

Read More

Interview with Ralph Snyderman from Duke University

Q: What are some of the critical contributions that academic institutions and medical centers are making to implement and accelerate precision medicine?

A: Over the past decade, the field of precision medicine has created technologies enabling far more personalized and effective health care delivery. Many of the most dramatic advances have come in the field of oncology but targeting care to the needs of the individual is rapidly achieving broader applications.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 16th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 20-23, 2019. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!
pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!